GI Hepatobiliary

Hepatocellular Carcinoma

Localized

- No Prior Therapy
  - 1st Line
    - IRB #2377: A humanitarian device exemption use protocol of TheraSphere for treatment of unresectable Hepatocellular Carcinoma
    - IRB #20410: New study to be available soon
  - No Trials Currently Available

- Prior Therapy
  - 2nd line
    - IRB #19185: Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma (LEAP-002)
    - IRB #17603: Phase 1-2 Study of ADI-PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma
  - No Trials Currently Available

Cholangiocarcinoma

- 1” Line
  - IRB # 20357: New study to be available soon

- 1” or 2” Line
  - IRB # 16033: New study to be available soon
  - IRB # 19095: A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)

CROSS-DISEASE TRIALS:

- IRB# TBD: EAY131 (MATCH)

http://www.ohsu.edu/research/rda/so/knight.php